Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
News|Articles|April 1, 2025
Q1 2025 Recap: Endocrinology News and Updates
Author(s)Patrick Campbell
Fact checked by: Connor Iapoce
Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.
Advertisement
Advertisement
The field of endocrinology, particularly
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss Beta Bionics' new insulin patch pump, expected to be commercialized in Q1 2027.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
Beta Bionics plans to launch Mint through the pharmacy channel in the first quarter of 2027.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.
Advertisement
Advertisement